GO:0007596 blood coagulation: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0007596 (blood coagulation) describes the sequential interaction of multiple coagulation factors that culminates in the formation of an insoluble fibrin clot.
• The process is classically divided into three stages: formation of prothrombin-converting principle, formation of thrombin, and formation of stable fibrin polymers.
• Coagulation is tightly regulated by anticoagulant pathways, and genetic defects in these pathways cause bleeding or thrombotic diseases.
• Key genes include F2, F5, F7, F8, F9, F10, F11, FGA, FGB, FGG, VWF, and PROC, among others.
• Molecular biology has clarified the structure and function of coagulation factors, enabling targeted research and therapeutic development.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) are powerful tools for dissecting coagulation factor function and disease mechanisms.
Description
Blood coagulation (GO:0007596) is the biological process in which multiple coagulation factors in the blood interact sequentially to form an insoluble fibrin clot. This process is essential for hemostasis and prevents excessive blood loss after vascular injury. The QuickGO definition divides coagulation into three stages: stage 1, formation of intrinsic and extrinsic prothrombin-converting principle; stage 2, formation of thrombin; and stage 3, formation of stable fibrin polymers. Dysregulation of coagulation underlies a wide range of bleeding and thrombotic disorders, making it a central topic in hematology and cardiovascular research. Understanding the molecular players and regulatory mechanisms is critical for developing diagnostics and therapeutics. This article provides a research-grade overview of GO:0007596, its key genes, disease associations, and modern methods for studying it, including CRISPR-based models.
blood coagulation At A Glance
| GO ID | GO:0007596 |
|---|---|
| GO term | blood coagulation |
| Ontology | biological_process |
| Synonym | blood clotting |
| Major function | Formation of an insoluble fibrin clot through sequential interaction of coagulation factors |
| Stage 1 | Formation of intrinsic and extrinsic prothrombin converting principle |
| Stage 2 | Formation of thrombin |
| Stage 3 | Formation of stable fibrin polymers |
| Regulation | Tightly controlled by anticoagulant pathways; genetic defects cause bleeding or thrombotic diseases |
What Is GO:0007596?
Blood coagulation is the sequential process in which the multiple coagulation factors of the blood interact, ultimately resulting in the formation of an insoluble fibrin clot; it may be divided into three stages: stage 1, the formation of intrinsic and extrinsic prothrombin converting principle; stage 2, the formation of thrombin; stage 3, the formation of stable fibrin polymers.
Why Is blood coagulation Important in Cell Biology?
Blood coagulation is vital for hemostasis, preventing excessive bleeding after injury, and its dysregulation leads to major human diseases including hemophilia, thrombosis, and cardiovascular disorders. Research into GO:0007596 informs the development of anticoagulant and procoagulant therapies, and molecular studies of coagulation factors have revealed genetic mechanisms of disease.
• Prevents blood loss after vascular injury by forming a fibrin clot.
• Genetic defects in coagulation factors cause bleeding disorders such as hemophilia.
• Hypercoagulable states contribute to thrombosis, stroke, and myocardial infarction.
• Anticoagulant pathways regulate coagulation to prevent inappropriate clotting.
• Coagulation factors are targets for therapeutic drugs (e.g., anticoagulants, replacement factors).
• Molecular biology of coagulation factors aids in genetic diagnosis and counseling.
• Coagulation intersects with inflammation and immune responses.
• Animal models and cell models are essential for studying coagulation mechanisms.
• CRISPR gene editing enables precise modeling of coagulation factor mutations.
• Understanding coagulation is fundamental for blood banking and transfusion medicine.
What Happens During blood coagulation?
Stage 1: Formation of prothrombin-converting principle
In simple terms: The first step is the activation of a complex that will convert prothrombin into thrombin.
Stage 1 of blood coagulation involves the formation of the intrinsic and extrinsic prothrombin converting principle, also known as the prothrombinase complex. The extrinsic pathway is initiated by tissue factor exposed at the site of injury, which activates factor VII, leading to activation of factor X. The intrinsic pathway is triggered by contact activation and involves factors XII, XI, IX, and VIII, also converging on factor X activation. Both pathways lead to the formation of the prothrombinase complex (factor Xa, factor Va, calcium, and phospholipids) that converts prothrombin to thrombin.
Stage 2: Formation of thrombin
In simple terms: Thrombin is the key enzyme that turns fibrinogen into fibrin.
In stage 2, prothrombin (factor II) is cleaved by the prothrombinase complex to generate thrombin (factor IIa). Thrombin is a serine protease that plays a central role in coagulation by converting fibrinogen to fibrin, activating platelets, and amplifying the coagulation cascade. Thrombin also activates factors V, VIII, XI, and XIII, and protein C, thus serving as a pivotal regulator.
Stage 3: Formation of stable fibrin polymers
In simple terms: Fibrin molecules assemble into a mesh that stabilizes the clot.
Stage 3 involves the conversion of fibrinogen to fibrin monomers by thrombin, followed by polymerization into fibrin polymers. Thrombin also activates factor XIII, which cross-links fibrin polymers, forming a stable insoluble clot. This cross-linking increases the mechanical strength and resistance of the clot to fibrinolysis.
Regulation by anticoagulant pathways
In simple terms: The body has natural brakes to prevent clots from growing too large.
Coagulation is regulated by anticoagulant pathways including antithrombin, protein C, protein S, and tissue factor pathway inhibitor. These inhibitors limit clot formation to the site of injury and prevent systemic thrombosis. Genetic defects in these pathways lead to thrombotic diseases, while defects in procoagulant factors cause bleeding disorders.
Key Genes Involved in GO:0007596 blood coagulation
The following genes encode key coagulation factors and regulators involved in GO:0007596.
| Gene | Major Role | Research Relevance |
|---|---|---|
| F2 | Prothrombin; precursor of thrombin | Mutations cause prothrombin deficiency or thrombosis |
| F5 | Factor V; cofactor in prothrombinase complex | Factor V Leiden mutation increases thrombosis risk |
| F7 | Factor VII; initiates extrinsic pathway | Deficiency causes bleeding; target for recombinant therapy |
| F8 | Factor VIII; cofactor in intrinsic pathway | Deficiency causes hemophilia A |
| F9 | Factor IX; serine protease in intrinsic pathway | Deficiency causes hemophilia B |
| F10 | Factor X; forms prothrombinase complex | Deficiency causes bleeding; target of anticoagulants |
| F11 | Factor XI; intrinsic pathway | Deficiency causes mild bleeding; role in thrombosis |
| FGA | Fibrinogen alpha chain | Mutations cause dysfibrinogenemia or afibrinogenemia |
| FGB | Fibrinogen beta chain | Mutations cause fibrinogen disorders |
| FGG | Fibrinogen gamma chain | Mutations cause fibrinogen disorders |
| VWF | von Willebrand factor; platelet adhesion and factor VIII carrier | Deficiency causes von Willebrand disease |
| PROC | Protein C; anticoagulant | Deficiency causes thrombosis |
| PROS1 | Protein S; cofactor for protein C | Deficiency causes thrombosis |
| SERPINC1 | Antithrombin; inhibits thrombin and factor Xa | Deficiency causes thrombosis |
| F13A1 | Factor XIII A subunit; cross-links fibrin | Deficiency causes bleeding |
| F13B | Factor XIII B subunit; carrier | Deficiency causes bleeding |
| PLG | Plasminogen; precursor of plasmin for fibrinolysis | Deficiency causes thrombosis |
| F12 | Factor XII; contact activation | Deficiency causes prolonged aPTT but no bleeding |
How Is blood coagulation Regulated?
Blood coagulation is regulated by anticoagulant pathways that prevent excessive clot formation. Antithrombin inhibits thrombin and factor Xa; protein C, activated by thrombin-thrombomodulin, degrades factors Va and VIIIa with protein S as cofactor; and tissue factor pathway inhibitor limits the extrinsic pathway. Genetic defects in these regulators cause thrombotic diseases.
blood coagulation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| F8 | Hemophilia A | Knockout mouse or cell model; point mutation for specific variants |
| F9 | Hemophilia B | Knockout or knock-in of patient mutations |
| F5 | Factor V Leiden thrombosis | Point mutation knock-in in cell lines or mice |
| F2 | Prothrombin G20210A thrombosis | Knock-in of mutation in hepatocyte cell lines |
| VWF | von Willebrand disease | Knockout or point mutation models |
Bleeding disorders
Deficiencies or dysfunction of coagulation factors such as factor VIII (hemophilia A), factor IX (hemophilia B), or von Willebrand factor (von Willebrand disease) lead to bleeding disorders. These conditions are caused by genetic mutations and are targets for replacement therapy and gene therapy.
Thrombotic disorders
Mutations in anticoagulant pathways, such as factor V Leiden, prothrombin G20210A, or deficiencies of protein C, protein S, or antithrombin, increase the risk of venous thrombosis. These genetic defects are important in clinical diagnostics and management.
Cardiovascular disease
Coagulation plays a role in arterial thrombosis, contributing to myocardial infarction and stroke. Anticoagulant and antiplatelet therapies target coagulation factors to prevent cardiovascular events.
From blood coagulation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of factor X affect clot formation? | F10 knockout cell line or mouse |
| Does a specific point mutation in F9 cause hemophilia B? | F9 point mutation knock-in |
| Can overexpression of protein C reduce thrombosis? | PROC overexpression cell model |
| How does factor V Leiden mutation affect coagulation? | F5 point mutation knock-in |
| What is the role of fibrinogen gamma chain in clot stability? | FGG knockout or tagged knock-in |
| Can CRISPR correct a coagulation factor mutation? | Knock-in of corrected sequence |
How to Study the blood coagulation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| PT/aPTT | Clotting time via extrinsic/intrinsic pathways | Diagnosis of bleeding disorders |
| Thrombin generation assay | Thrombin production over time | Assessment of hyper- or hypocoagulability |
| DNA sequencing | Mutations in coagulation genes | Genetic diagnosis |
| Western blot | Protein levels of coagulation factors | Research on expression |
| ELISA | Antigen levels of factors | Quantification in plasma |
| CRISPR knockout | Gene function loss | Target validation |
| CRISPR knock-in | Specific mutations | Disease modeling |
Coagulation assays
PT, aPTT, and thrombin generation assays measure the functional activity of coagulation pathways. These are used to diagnose bleeding or thrombotic disorders.
Genetic analysis
DNA sequencing identifies mutations in coagulation factor genes, aiding diagnosis and research.
Cell models
Hepatocyte cell lines (e.g., HepG2) expressing coagulation factors are used to study synthesis and secretion.
Animal models
Knockout and transgenic mice model coagulation factor deficiencies and thrombotic disorders.
How CRISPR Can Be Used to Study GO:0007596 blood coagulation
Knockout
CRISPR knockout of coagulation factor genes in cell lines or mice can reveal their role in clot formation and hemostasis.
Point Mutation
Introducing specific point mutations (e.g., factor V Leiden) via CRISPR allows study of their impact on coagulation and thrombosis.
Knock-in
Knock-in of patient-derived mutations or tagged versions of coagulation factors enables precise disease modeling and protein tracking.
Overexpression
Overexpression of anticoagulant factors like protein C can be used to study their protective effects against thrombosis.
How EDITGENE Supports blood coagulation Research
Researchers studying blood coagulation-related genes often need to determine whether a candidate gene is causally involved in clot formation or disease. EDITGENE provides comprehensive CRISPR services to create precise cellular and animal models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for blood coagulation research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| GNA12 Knockout HEK293 Cell Line | EDJ-KQ173 | Human | 2768 | Details Get a Quote |
| GNAQ Knockout HEK293 Cell Line | EDJ-KQ202 | Human | 2776 | Details Get a Quote |
| F2RL1 Knockout HEK293T Cell Line | EDJ-KQ222 | Human | 2150 | Details Get a Quote |
| ANO6 Knockout HEK293 Cell Line | EDJ-KQ228 | Human | 196527 | Details Get a Quote |
| ANGPT4 Knockout HEK293 Cell Line | EDJ-KQ606 | Human | 51378 | Details Get a Quote |
| F2R Knockout HEK293 Cell Line | EDJ-KQ793 | Human | 2149 | Details Get a Quote |
| ITGA2 Knockout HEK293 Cell Line | EDJ-KQ809 | Human | 3673 | Details Get a Quote |
| ITGB3 Knockout HEK293 Cell Line | EDJ-KQ818 | Human | 3690 | Details Get a Quote |
| VWF Knockout HEK293 Cell Line | EDJ-KQ878 | Human | 7450 | Details Get a Quote |
| ANGPT1 Knockout HEK293 Cell Line | EDJ-KQ1201 | Human | 284 | Details Get a Quote |
| F2RL3 Knockout HEK293 Cell Line | EDJ-KQ1286 | Human | 9002 | Details Get a Quote |
| P2RY1 Knockout HEK293 Cell Line | EDJ-KQ1287 | Human | 5028 | Details Get a Quote |
| ADORA2A Knockout HEK293 Cell Line | EDJ-KQ1290 | Human | 135 | Details Get a Quote |
| PLAT Knockout HEK293 Cell Line | EDJ-KQ1465 | Human | 5327 | Details Get a Quote |
| ITPK1 Knockout HEK293 Cell Line | EDJ-KQ1683 | Human | 3705 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »
Frequently Asked Questions About blood coagulation
What is blood coagulation (GO:0007596)?
Blood coagulation is the sequential process in which multiple coagulation factors interact to form an insoluble fibrin clot, divided into three stages: prothrombin-converting principle formation, thrombin formation, and stable fibrin polymer formation.
What genes are involved in blood coagulation?
Key genes include F2, F5, F7, F8, F9, F10, F11, FGA, FGB, FGG, VWF, PROC, PROS1, SERPINC1, F13A1, F13B, PLG, and F12.
What are the three stages of blood coagulation?
Stage 1: formation of intrinsic and extrinsic prothrombin converting principle; stage 2: formation of thrombin; stage 3: formation of stable fibrin polymers.
How is blood coagulation regulated?
It is regulated by anticoagulant pathways including antithrombin, protein C, protein S, and tissue factor pathway inhibitor.
What diseases are associated with blood coagulation defects?
Bleeding disorders (e.g., hemophilia A and B, von Willebrand disease) and thrombotic disorders (e.g., factor V Leiden, prothrombin G20210A).
What is the role of thrombin in coagulation?
Thrombin converts fibrinogen to fibrin, activates platelets, and amplifies the coagulation cascade.
How can CRISPR be used to study blood coagulation?
CRISPR can create knockout, point mutation, knock-in, and overexpression models to dissect gene function and model diseases.
What are common laboratory tests for blood coagulation?
PT, aPTT, and thrombin generation assays measure clotting function.
What is the difference between intrinsic and extrinsic pathways?
The extrinsic pathway is initiated by tissue factor, while the intrinsic pathway is triggered by contact activation; both converge on factor X activation.
Why is blood coagulation important for human health?
It prevents blood loss after injury, and its dysregulation causes bleeding or thrombosis, impacting cardiovascular health.
Conclusion
Blood coagulation (GO:0007596) is a fundamental biological process with critical roles in hemostasis and disease. Understanding its molecular mechanisms, key genes, and regulatory pathways is essential for developing diagnostics and therapeutics. CRISPR-based models offer powerful tools to study coagulation factors and their mutations, advancing both basic research and clinical translation.
References
- 1. Stubbs JR. 1996. Coagulation for blood bankers.. Clin Lab Med 16(4):837-71 PMID: 8974198
- 2. Dahlbäck B. 2005. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases.. J Intern Med 257(3):209-23 PMID: 15715678
- 8. Oldenburg J et al.. 2001. Molecular biology of blood coagulation.. Semin Thromb Hemost 27(4):313-24 PMID: 11547354
